Alzheimer's disease

News

Researchers have found that people with early Alzheimer's are not following guidelines for promoting brain health, even if they are on drug therapy.

News

Biogen/Eisai's Alzheimer's drug Leqembi continued to grow in Q2, driven by a new subcutaneous version, but fell a little short of expectations.

News

Biogen and Ionis have revealed the first clinical results with tau-targeting Alzheimer's drug candidate diranersen, to a mixed response.

News

The FDA has cleared Eisai and Biogen's Leqembi Iqlik subcutaneous injection as a starting dose, removing the need for regular infusion clinic visits.

News

Biogen will advance its tau-targeting Alzheimer's disease drug diranersen into phase 3, even though it missed the main endpoint in a midstage trial.

R&D

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.